

INFORMAZIONI PERSONALI

Eriseld Krasniqi

ESPERIENZE LAVORATIVE

Febbraio 2021 - Presente

IRCCS Istituto Nazionale dei Tumori Regina Elena
Dirigente Medico Oncologo

Dicembre 2018 – Gennaio 2021

IRCCS Istituto Nazionale dei Tumori Regina Elena
Oncologo Specialista con contratto a tempo determinato

Agosto 2013 – Settembre 2018

Specializzazione in Oncologia Medica
Università degli Studi di Roma Tor Vergata

Luglio 2011 – Agosto 2013

Medicina Generale
In libera professione

ISTRUZIONE

Agosto 2013 – Settembre 2018

Specializzazione in Oncologia Medica
Università degli Studi di Roma Tor Vergata

Ottobre 2003 – Ottobre 2010

Laurea in Medicina e Chirurgia
Università degli Studi di Roma Tor Vergata

2009 – 2003

Liceo Scientifico

Lingue

Inglese (last IELTS: 7, 7, 7, 7, 8), Italiano, Albanese (madrelingua), Turco (livello intermedio), Tedesco (Livello elementare), Cinese Mandarino (livello elementare)

INFORMAZIONI AGGIUNTIVE

Pubblicazioni

[The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature.](#)

Botticelli A, Fabbri A, Roberto M, Alesini D, Cirillo A, D'Auria G, Krasniqi E, Marrucci E, Muratore M, Pantano F, Pizzuti L, Portarena I, Rossi R, Scagnoli S, Marchetti P. *Front Oncol.* 2022 Feb 9;12:797157

[PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.](#)

Pizzuti L, Krasniqi E, Sperduti I, ..., Botti C, Tomao F, Cappelli S, Bon G, Pelle F, Cavicchi F, Fiorio E, Foglietta J, Scagnoli S, Marchetti P, Ciliberto G, Vici P. *Ther Adv Med Oncol.* 2021 Nov 29;13:17588359211059873. doi: 10.1177/17588359211059873. eCollection 2021.

[KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy.](#) Scalera S, Mazzotta M, Corleone G, Sperati F, Terrenato I, Krasniqi E, Pizzuti L, Barba

M, Vici P, Gallo E, Buglioni S, Visca P, Pescarmona E, Marinelli D, De Nicola F, Ciuffreda L, Goeman F, Fanciulli M, Giusti R, Vecchione A, De Maria R, Cappuzzo F, Marchetti P, Ciliberto G, Maugeri-Saccà M.

[Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?](#) Mazzotta M, Pizzuti L, Krasniqi E, Di Lisa FS, Cappuzzo F, Landi L, Sergi D, Pelle F, Cappelli S, Botti C, Vizza E, Tomao S, Marchetti L, Sanguineti G, Botticelli A, Marchetti P, Magri V, Pisegna S, Venuti A, Tomao F, Buzzacchino F, Ciliberto G, Barba M, Vici P.

[Prognostic Relevance of Neutrophil to Lymphocyte Ratio \(NLR\) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting.](#) Grassadonia A, Graziano V, Iezzi L, Vici P, Barba M, Pizzuti L, Cicero G, Krasniqi E, Mazzotta M, Marinelli D, Amodio A, Natoli C, Tinari N.

[MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNomics study.](#) Krasniqi E, Sacconi A, Marinelli D, Pizzuti L, Mazzotta M, Sergi D, Capomolla E, Donzelli S, Carosi M, Bagnato A, Gamucci T, Tomao S, Natoli C, Marchetti P, Grassadonia A, Tinari N, De Tursi M, Vizza E, Ciliberto G, Landi L, Cappuzzo F, Barba M, Blandino G, Vici P.

[The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.](#) Pizzuti L, Barba M, Mazzotta M, Krasniqi E, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E, Generali D, La Verde N, Cassano A, Bria E, Moscetti L, Michelotti A, Adamo V, Zamagni C, Tonini G, Sergi D, Marinelli D, Paoletti G, Tomao S, Botticelli A, Marchetti P, Tinari N, Grassadonia A, Valerio MR, Mirabelli R, Fabbri MA, D'Ostilio N, Veltri E, Corsi D, Garrone O, Paris I, Sarobba G, Meattini I, Pistelli M, Giotta F, Lorusso V, Garufi C, Russo A, Cazzaniga M, Del Medico P, Roselli M, Vaccaro A, Perracchio L, di Benedetto A, Daraloti T, Sperduti I, De Maria R, Di Leo A, Sanguineti G, Ciliberto G, Vici P.

[COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience](#) M Barba, **E Krasniqi**, L Pizzuti, M Mazzotta, D Marinelli... - The Breast Journal, 2021

[Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial](#)
E Krasniqi, L Pizzuti, MR Valerio, E Capomolla, C Botti... - Int J Med Sci, 2021

[Burnout of health care providers during the COVID-19 pandemic: Focus on Medical Oncologists](#)
P Vici, **E Krasniqi**, L Pizzuti, G Ciliberto, M Mazzotta... - International Journal of Medical Sciences, 2021

[CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives](#)
M Roberto, A Astone, A Botticelli, L Carbognin...**E Krasniqi**... - Cancers, 2021

[Multicohort and cross-platform validation of a prognostic Wnt signature in colorectal cancer.](#)
F Goeman, FN De, CA Amoreo, S Scalera, D Marinelli...**E Krasniqi**... - Clinical and translational medicine, 2020

[Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study](#)
G Bon, L Pizzuti, V Laquintana, R Loria, M Porru...**E Krasniqi**... - Journal of Experimental & Clinical Cancer Research, 2020

[KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden](#)
D Marinelli, M Mazzotta, S Scalera, I Terrenato...**E Krasniqi**... - Annals of Oncology, 2020

[Cancer patients and coronavirus disease 2019: evidence in context](#)
M Barba, **E Krasniqi**, G Ciliberto, P Vici - Journal of Translational Medicine, 2020

[Palliative and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives: Authors](#)
D Marinelli, R Giusti, M Mazzotta, M Filetti, **E Krasniqi**... - Critical Reviews in Oncology/Hematology, 2020

[Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence](#)
E Krasniqi, L Pizzuti, G Barchiesi, D Sergi, S Carpano... - Journal of cellular physiology, 2020

[Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials](#)
D Marinelli, M Mazzotta, L Pizzuti, **E Krasniqi**... - Cancers, 2020

[Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane](#)

E Krasniqi, G Barchiesi, M Mazzotta, L Pizzuti, A Villa... - Medicine, 2020

[Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors](#)

P Vici, L Pizzuti, **E Krasniqi**, A Botticelli, G Ciliberto... - 2020

[Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial](#)

L Pizzuti, **E Krasniqi**, C Mandoj, D Marinelli, D Sergi... - Cancers, 2020

[Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting](#)

L Pizzuti, **E Krasniqi**, G Barchiesi, M Della Giulia, F Izzo... - International journal of cancer, 2020

[Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes](#)

M Mazzotta, M Filetti, M Occhipinti, D Marinelli...**E Krasniqi**... - Journal for immunotherapy of cancer, 2020

[Neoadjuvant endocrine therapy in breast cancer: current knowledge and future perspectives](#)

G Barchiesi, M Mazzotta, **E Krasniqi**, L Pizzuti... - International Journal of Molecular Sciences, 2020

[Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives](#)

E Krasniqi, G Barchiesi, L Pizzuti, M Mazzotta, A Venuti... - Journal of hematology & oncology, 2019

[Mutations in the KEAP1-NFE2L2 pathway define a molecular subset of rapidly progressing lung adenocarcinoma](#)

F Goeman, F De Nicola, S Scalera, F Sperati, E Gallo...**E Krasniqi**... - Journal of Thoracic Oncology, 2019

[Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report](#)

G Barchiesi, **E Krasniqi**, M Barba, M Della Giulia... - Medicine, 2019

[Long-term safety and real-world effectiveness of trastuzumab in breast cancer](#)

M Mazzotta, **E Krasniqi**, G Barchiesi, L Pizzuti, F Tomao... - Journal of clinical medicine, 2019

[Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios](#)

L Pizzuti, **E Krasniqi**, G Barchiesi, M Mazzotta, M Barba... - Journal of Cancer, 2019

[Ketogenic diet and other dietary intervention strategies in the treatment of cancer](#)

M Vergati, **E Krasniqi**, GD Monte, S Riondino... - Current medicinal chemistry, 2017

[Cisplatin plus capecitabine \(CisCape\) and concurrent pelvic radiotherapy for the neoadjuvant treatment of rectal cancer \(RC\)](#)

V Formica, L Martano, A Nardecchia, M Benassi...**E Krasniqi**... - Annals of Oncology, 2015

[Emerging role of S-1 in gastric cancer](#)

E Krasniqi, S Pellicori, V Formica - Indian journal of medical and paediatric oncology ..., 2015

Altro

Speaker at different National conferences or other events on Cancer

Associazioni

Registered in Rome Medical Council, nr: 58843

Registered in Irish medical council, nr: 406987 (currently in "withdrawal" status)

Certificazioni

-ALS (Advanced Life Support) training (March 2014, July 2019)

-Quality Management Systems in Health Structures Course [UNI EN ISO 9001:2008]